A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Kortylewski, Marcin, Ph.D. Laboratory Bookmark and Share

Laboratory Overview

We focus our studies on identification of therapeutic targets among signaling molecules which are involved in tumor-promoting inflammation. Our two-step immunotherapeutic strategy is first to disarm tumor defense systems, and then to activate immune attack from within.

Research Interests
 
Fighting cancer by activating immune system to search and destroy tumor cells with high precision could overcome the problem of serious side-effects observed after conventional cancer treatments. Recent advances in the understanding interactions between tumor and immune system identified that immune cells accumulated within tumor tissue are essential therapeutic targets for cancer immunotherapy. Dysfunctional immune cell populations within the tumor microenvironment secrete growth factors, promote blood vessel formation and disarm the immune system. Targeting immune cells in tumors poses problems due to the lack of specific therapeutics. We previously developed a novel reagent, CpG-siRNA molecules that allow for specific receptor-mediated delivery of the therapeutic agent (siRNA) into certain immune cell populations. We used CpG-siRNAs to block function of tumor-supporting immune cells, thereby generating potent antitumor immune responses in mice. Our recent studies suggest that the same strategy could restore the antitumor immune responses in cancer patients. Moreover, we used CpG-siRNAs to block oncogenic signaling and induce cell death in several types of human blood cancers, including acute myeloid leukemia (AML). We currently optimize CpG-siRNAs for use against metastatic tumors and multiple gene targets, what should generate novel, more effective and safer therapeutics, expanding treatment options for the benefit of cancer patients.
 
Contact Information
 
To request expert commentary on Immunotherapy, contact  Media Relations at 800-888-5323 or media@coh.org.

To reach me or my staff, call 626-256-4673, ext. 84120.
 
Lab Members
 
Priyanka Duttagupta, Postdoctoral Fellow
pduttagupta@coh.org
626-256-4673, ext. 64437
 
Dayson Friaca Moreira, Postdoctoral Fellow
dmoreira@coh.org
626-256-4673, ext. 64437
 
Marc Lucia Perez, Postdoctoral Fellow
mlperez@coh.org
626-256-4673, ext. 32122
 
Hae Jung Won, Postdoctoral Fellow
hjwon@coh.org
626-256-4673, ext. 64437
 
Xingli Zhao, Pre-doctoral Fellow
xzhao@coh.org
626-256-4673, ext. 32122
 
 
 

Kortylewski, Marcin, Ph.D. Laboratory

Laboratory Overview

We focus our studies on identification of therapeutic targets among signaling molecules which are involved in tumor-promoting inflammation. Our two-step immunotherapeutic strategy is first to disarm tumor defense systems, and then to activate immune attack from within.

Research Interests
 
Fighting cancer by activating immune system to search and destroy tumor cells with high precision could overcome the problem of serious side-effects observed after conventional cancer treatments. Recent advances in the understanding interactions between tumor and immune system identified that immune cells accumulated within tumor tissue are essential therapeutic targets for cancer immunotherapy. Dysfunctional immune cell populations within the tumor microenvironment secrete growth factors, promote blood vessel formation and disarm the immune system. Targeting immune cells in tumors poses problems due to the lack of specific therapeutics. We previously developed a novel reagent, CpG-siRNA molecules that allow for specific receptor-mediated delivery of the therapeutic agent (siRNA) into certain immune cell populations. We used CpG-siRNAs to block function of tumor-supporting immune cells, thereby generating potent antitumor immune responses in mice. Our recent studies suggest that the same strategy could restore the antitumor immune responses in cancer patients. Moreover, we used CpG-siRNAs to block oncogenic signaling and induce cell death in several types of human blood cancers, including acute myeloid leukemia (AML). We currently optimize CpG-siRNAs for use against metastatic tumors and multiple gene targets, what should generate novel, more effective and safer therapeutics, expanding treatment options for the benefit of cancer patients.
 
Contact Information
 
To request expert commentary on Immunotherapy, contact  Media Relations at 800-888-5323 or media@coh.org.

To reach me or my staff, call 626-256-4673, ext. 84120.
 
Lab Members
 
Priyanka Duttagupta, Postdoctoral Fellow
pduttagupta@coh.org
626-256-4673, ext. 64437
 
Dayson Friaca Moreira, Postdoctoral Fellow
dmoreira@coh.org
626-256-4673, ext. 64437
 
Marc Lucia Perez, Postdoctoral Fellow
mlperez@coh.org
626-256-4673, ext. 32122
 
Hae Jung Won, Postdoctoral Fellow
hjwon@coh.org
626-256-4673, ext. 64437
 
Xingli Zhao, Pre-doctoral Fellow
xzhao@coh.org
626-256-4673, ext. 32122
 
 
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.

Learn more about
City of Hope's institutional distinctions, breakthrough innovations and collaborations.
 
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • It was 2009 when a City of Hope patient in her 40s learned that the cancer she had been fighting for several years had metastasized to her lungs. Her medical team ran genetic tests on the tumor, but none of the drug therapies available at the time targeted the known mutations in the tumor cells. […]
  • Acute myeloid leukemia (AML) is characterized by a rapidly-developing cancer in the myeloid line of blood cells, which is responsible for producing red blood cells, platelets and several types of white blood cells called granulocytes. Because AML grows rapidly, it can quickly crowd out normal blood cells, leadi...
  • Rachel Divine is a yoga therapist and patient leader for the Sheri & Les Biller Patient and Family Resource Center. She’s also a former City of Hope patient. When someone you know has cancer, even the word “cancer” can make you feel nervous, sleepless, depressed or more. But, as a yoga teacher for 15 ...
  •   Diagnosed with type 1 diabetes when she was 9 years old, Gina Marchini accepted the fact that she would need insulin the rest of her life. Every day, she injected herself with the lifesaving hormone. She also carefully controlled her diet and monitored the rise and fall of her blood glucose with military...
  • The defeat of cancer will require a team effort. Nowhere is this more necessary (or apparent) than in efforts to combat two of the most deadly forms of the disease  – pancreatic cancer and triple-negative breast cancer. It’s the approach City of Hope is taking with its newly launched multidisciplinary teams, br...
  • It’s a reasonable question: Why is the National Cancer Institute funding a study on preventing heart failure? The answer is reasonable as well: Rates of heart failure are drastically high among childhood cancer survivors — 15 times higher than among people the same age who were never treated for cancer. T...
  • Many teenagers take a break from academics during the summer, but not the eight high school students enrolled in the California Institute for Regenerative Medicine (CIRM) Creativity Awards program at City of Hope. They took the opportunity to obtain as much hands-on research experience as possible, learning fro...
  • About one in eight women will develop breast cancer at some point in her life. In fact, breast cancer is the most common cancer in American women, behind skin cancer. Although women can’t change some risk factors, such as genetics and the natural aging process, there are certain things they can do to lower thei...
  • As genetic testing becomes more sophisticated, doctors and their patients are finding that such tests can lead to the discovery of previously unknown cancer risks. In his practice at City of Hope, Thomas Slavin, M.D., an assistant clinical professor in the Division of Clinical Cancer Genetics, sees the full spe...
  • And the winners are … everyone in the San Gabriel Valley. The recipients of City of Hope’s first-ever Healthy Living grants have been announced, and the future is looking healthier already. In selecting San Gabriel Valley organizations to receive the grants, City of Hope’s Community Benefits Advisory Council ch...
  • Barry Leshowitz is a former City of Hope patient and a family advisor for the Sheri & Les Biller Patient and Family Resource Center. It’s been almost seven years since I checked into a local hospital in Phoenix for a hip replacement, only to be informed by the surgeon that he had canceled the surgery....
  • When it comes to science, the best graduate schools don’t just train scientists, they prepare their students for a lifetime of learning, accomplishment and positive impact on society. At City of Hope, the Irell & Manella Graduate School of Biological Sciences goes one step further – by preparing students to...
  • Cancer affects not just the cancer patient, but everyone around him or her, even after treatment is complete. The challenges can include the fear of cancer recurrence, coping with cancer’s economic impact and the struggle to achieve work-life balance post-treatment. Family members and loved ones of cancer patie...
  •   Bladder cancer facts: Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. 2015 estimates: 74,000 new cases of bladder cancer diagnosed 16,000 deaths from bladder cancer (about 11,510 in men and 4,490 in women) Risk factors for bladder cancer: Smoking: Smokers...
  • Women with ovarian cancer have questions about the most promising treatment options, revolutionary research avenues, survivorship and, of course, the potential impact on their personal lives. Now, together in one place, are experts who can provide answers. On Saturday, Sept. 12, the 2015 Ovarian Cancer Survivor...